目的研究复方苦参注射液对乳腺癌模型大鼠的改善作用。方法按照随机数字法选雄性SD大鼠15只为正常组,余采用腹腔注射甲基亚硝基脲(MNU)复制大鼠乳腺癌模型。按随机数字表法将造模成功大鼠随机分为5组:模型组,对照组,大中小3个剂量实验组,各15只。从造模成功第2天开始,实验组腹腔注射复方苦参注射液80,40,20 m L·kg~(-1),模型组灌胃三苯氧胺混悬液40 m L·kg~(-1),对照组和正常组大鼠灌胃生理盐水4 m L·kg~(-1),每组均1次/天。干预9周后,用酶联免疫吸附法测定大鼠血清中的雌二醇(E2)与存活素含量、乳腺组织内的细胞增殖抗原标记物(Ki67)、抑癌基因p53(P53)及组织和血清的程序性细胞死亡因子4(PDCD4)水平。结果正常组、对照组、小中大3个剂量实验组和模型组的E2含量分别为(36.92±1.28),(70.09±1.91),(64.40±2.77),(40.49±2.17),(40.49±2.39),(49.56±1.27)ng·L~(-1);这6组的Ki67分别为(15.72±0.76),(70.25±1.59),(65.41±1.33),(21.03±1.50),(21.30±1.10),(40.91±1.85)ng·L~(-1);这6组的P53分别为(10.63±0.89),(50.41±1.73),(45.04±2.09),(11.83±1.29),(12.18±1.48),(28.37±1.66)ng·L~(-1);这6组的存活素分别为(5.95±0.46),(63.91±1.96),(30.85±1.63),(16.96±0.53),(16.58±0.95),(25.36±1.51)ng·L~(-1);这6组的组织PDCD4分别为(101.06±2.49),(31.12±1.37),(35.25±1.13),(79.62±1.73),(79.52±1.45),(56.40±2.82)ng·L~(-1);这6组的血清PDCD4分别为(22.00±1.56),(6.93±0.62),(7.78±0.67),(19.92±1.01),(19.13±4.42),(15.34±1.02)ng·L~(-1)。与对照组相比,中高2个剂量实验组与模型组血清E2、存活素、组织Ki67与P53水平降低,差异有统计学意义(均P<0.05);与模型组比较,中高2个剂量实验组的血清E2、存活素、组织Ki67与P53水平较低,差异有统计学意义(均P<0.05)。与对照组比较,中高2个剂量实验组与模型组组织与血清PDCD4水平较高,差异有统计学意义(P<0.05);与模型组比较,中高2个剂量实验组的组织与血清PDCD4水平较高,差异有统计学意义(P<0.05)。结论复方苦参注射液能够明显改善乳腺癌模型大鼠Ki67、存活素、P53及PDCD4水平。 Objective To study the effect of compound Kushen injection on breast cancer model rats. Methods According to the random number method, 15 male SD rats were selected as the normal group. The rats were injected intraperitoneally with methyl nitrosourea (MNU) to replicate the rat model of breast cancer. According to the random number table, the successful model rats were randomly divided into 5 groups: model group, control group, medium, small and medium dose three experimental groups, each 15 rats. From the second day of successful model establishment, the experimental group was injected intraperitoneally with Compound Kushen Injection 80, 40 and 20 m L · kg -1, and the model group was orally administered with tamoxifen 40 mL · kg -1 ). The rats in the control group and the normal group were given normal saline (4 m L · kg -1) once a day for one week. After intervention for 9 weeks, the contents of estradiol (E2) and survivin, the expression of cell proliferation antigen marker (Ki67), p53 (P53) and tissue in breast tissue were determined by enzyme-linked immunosorbent assay And serum levels of programmed cell death factor 4 (PDCD4). Results The contents of E2 in the normal group, control group, small and middle sized groups were (36.92 ± 1.28), (70.09 ± 1.91), (64.40 ± 2.77), (40.49 ± 2.17) and (40.49 ± 2.39 and 49.56 ± 1.27 ng · L -1, respectively. Ki67 in these 6 groups were (15.72 ± 0.76), (70.25 ± 1.59), (65.41 ± 1.33), (21.03 ± 1.50) and (21.30 ± 1.10 and 40.91 ± 1.85 ng · L -1, respectively. The P53 of these 6 groups were (10.63 ± 0.89), (50.41 ± 1.73), (45.04 ± 2.09) and (11.83 ± 1.29) (18.18 ± 1.48) and (28.37 ± 1.66) ng · L -1, respectively. The survivals in these 6 groups were (5.95 ± 0.46), (63.91 ± 1.96), (30.85 ± 1.63) and (16.96 ± 0.53) , (16.58 ± 0.95) and (25.36 ± 1.51) ng · L -1, respectively. The PDCD4 in these 6 groups were (101.06 ± 2.49), (31.12 ± 1.37), (35.25 ± 1.13) and (79.62 ± 1.73, 79.52 ± 1.45 and 56.40 ± 2.82 ng · L -1, respectively. The serum PDCD4 of these 6 groups were (22.00 ± 1.56), (6.93 ± 0.62), (7.78 ± 0.67) and 19.92 ± 1.01), (19.13 ± 4.42) and (15.34 ± 1.02) ng · L -1, respectively. Compared with the control group, the levels of serum E2, survivin, tissue Ki67 and P53 in the two experimental groups and the model group decreased significantly (both P <0.05) Serum E2, survivin, tissue Ki67 and P53 levels were lower in the two groups (all P <0.05). Compared with the control group, the levels of PDCD4 in the high-dose and high-dose two experimental groups and the model group were significantly higher than those in the model group (P <0.05); Compared with the model group, the PDCD4 levels in the two high- Higher, the difference was statistically significant (P <0.05). Conclusion Compound Kushen injection can significantly improve Ki67, survivin, P53 and PDCD4 levels in breast cancer model rats.